
Histologic variants (HV) of urothelial carcinoma (UC-V) and non-urothelial carcinomas (NUC) of the bladder and urinary tract are aggressive malignancies with poor prognosis and limited response to platinum-based chemotherapy. Despite their biological particularities and distinct immune microenvironments,...

Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for metastatic or locally advanced urothelial carcinoma (m/laUC). Real-world patients frequently present with unfavorable clinical characteristics, raising uncertainty about whether outcomes mirror those of the pivotal EV-302/KEYNOTE-A39...

The advent of the Intuitive da Vinci single-port (SP) robotic system represents a pivotal evolution in minimally invasive urologic surgery, offering enhanced dexterity, improved surgical ergonomics, and reduced patient morbidity. This review is designed to provide a comprehensive evaluation of current...

Precise perioperative risk stratification for upper tract urothelial carcinoma (UTUC) is essential. We developed a multimodal prognostic model integrating perioperative clinical data, radiomics, and deep learning (DL) features from baseline CT urography to improve survival prediction and guide adjuvant...